Latest Frazier Life Sciences Management, L.P. Stock Portfolio
Frazier Life Sciences Management, L.P. Performance:
2025 Q3: 32.37%YTD: 33.45%2024: 15.8%
Performance for 2025 Q3 is 32.37%, and YTD is 33.45%, and 2024 is 15.8%.
About Frazier Life Sciences Management, L.P. and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Frazier Life Sciences Management, L.P. reported an equity portfolio of $3.3 Billions as of 30 Sep, 2025.
The top stock holdings of Frazier Life Sciences Management, L.P. are MIRM, NAMS, VRNA. The fund has invested 14.9% of it's portfolio in MIRUM PHARMACEUTICALS INC and 14.2% of portfolio in NEWAMSTERDAM PHARMA COMPANY.
The fund managers got completely rid off HILLEVAX INC (HLVX), CG ONCOLOGY INC and COGENT BIOSCIENCES INC (COGT) stocks. They significantly reduced their stock positions in TRAVERE THERAPEUTICS INC (TVTX), CRESCENT BIOPHARMA INC. and ALKERMES PLC (ALKS). Frazier Life Sciences Management, L.P. opened new stock positions in ABIVAX SA, ACADIA PHARMACEUTICALS INC (ACAD) and ASSEMBLY BIOSCIENCES INC (ASMB). The fund showed a lot of confidence in some stocks as they added substantially to ADVERUM BIOTECHNOLOGIES INC (ADVM), DYNE THERAPEUTICS INC (DYN) and CYTOKINETICS INC (CYTK).
The top stock holdings of Frazier Life Sciences Management, L.P. are MIRM, NAMS, VRNA. The fund has invested 14.9% of it's portfolio in MIRUM PHARMACEUTICALS INC and 14.2% of portfolio in NEWAMSTERDAM PHARMA COMPANY.
The fund managers got completely rid off HILLEVAX INC (HLVX), CG ONCOLOGY INC and COGENT BIOSCIENCES INC (COGT) stocks. They significantly reduced their stock positions in TRAVERE THERAPEUTICS INC (TVTX), CRESCENT BIOPHARMA INC. and ALKERMES PLC (ALKS). Frazier Life Sciences Management, L.P. opened new stock positions in ABIVAX SA, ACADIA PHARMACEUTICALS INC (ACAD) and ASSEMBLY BIOSCIENCES INC (ASMB). The fund showed a lot of confidence in some stocks as they added substantially to ADVERUM BIOTECHNOLOGIES INC (ADVM), DYNE THERAPEUTICS INC (DYN) and CYTOKINETICS INC (CYTK).
Frazier Life Sciences Management, L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that Frazier Life Sciences Management, L.P. made a return of 32.37% in the last quarter. In trailing 12 months, it's portfolio return was 32.54%.
New Buys
| Ticker | $ Bought |
|---|---|
| abivax sa | 32,117,700 |
| acadia pharmaceuticals inc | 13,099,300 |
| assembly biosciences inc | 11,680,000 |
| engene holdings inc | 7,904,900 |
New stocks bought by Frazier Life Sciences Management, L.P.
Additions
| Ticker | % Inc. |
|---|---|
| adverum biotechnologies inc | 94.29 |
| dyne therapeutics inc | 80.49 |
| cytokinetics inc | 60.52 |
| valneva se | 57.14 |
| zai lab ltd | 24.4 |
| mbx biosciences inc | 11.14 |
| evolus inc | 8.01 |
| kalvista pharmaceuticals inc | 3.11 |
Additions to existing portfolio by Frazier Life Sciences Management, L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| travere therapeutics inc | -60.87 |
| crescent biopharma inc. | -39.84 |
| alkermes plc | -29.98 |
| jade biosciences inc | -20.25 |
| tarsus pharmaceuticals inc | -16.46 |
| disc medicine inc | -13.07 |
| maze therapeutics inc | 0.00 |
Frazier Life Sciences Management, L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| hillevax inc | -21,128,000 |
| elevation oncology inc | -2,200,240 |
| cogent biosciences inc | -12,454,400 |
| oric pharmaceuticals inc | -10,813,100 |
| cg oncology inc | -20,020,000 |
| oruka therapeutics inc | -6,539,100 |
Frazier Life Sciences Management, L.P. got rid off the above stocks
Sector Distribution
Frazier Life Sciences Management, L.P. has about 84.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 84.8 |
| Others | 15.2 |
Market Cap. Distribution
Frazier Life Sciences Management, L.P. has about 1.7% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 33.9 |
| UNALLOCATED | 30.9 |
| MID-CAP | 29.1 |
| MICRO-CAP | 4 |
| LARGE-CAP | 1.7 |
Stocks belong to which Index?
About 55.1% of the stocks held by Frazier Life Sciences Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 55.1 |
| Others | 44.9 |
Frazier Life Sciences Management, L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P. has 47 stocks in it's portfolio. About 69.5% of the portfolio is in top 10 stocks. EOLS proved to be the most loss making stock for the portfolio. NAMS was the most profitable stock for Frazier Life Sciences Management, L.P. last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACAD | acadia pharmaceuticals inc | 0.39 | 613,837 | 13,099,300 | new | |||
| ADVM | adverum biotechnologies inc | 0.28 | 2,077,430 | 9,410,760 | added | 94.29 | ||
| AGIO | agios pharmaceuticals inc | 1.54 | 1,279,750 | 51,369,300 | unchanged | 0.00 | ||
| AKRO | akero therapeutics inc | 0.52 | 366,784 | 17,414,900 | unchanged | 0.00 | ||
| ALKS | alkermes plc | 0.63 | 700,647 | 21,019,400 | reduced | -29.98 | ||
| ALLO | allogene therapeutics inc | 0.14 | 3,868,750 | 4,797,250 | unchanged | 0.00 | ||
| ARQT | arcutis biotherapeutics inc | 5.58 | 9,874,510 | 186,135,000 | unchanged | 0.00 | ||
| ASMB | assembly biosciences inc | 0.35 | 456,249 | 11,680,000 | new | |||
| AURA | aura biosciences inc | 0.94 | 5,100,000 | 31,518,000 | unchanged | 0.00 | ||
| AUTL | autolus therapeutics plc | 0.23 | 4,623,320 | 7,536,020 | unchanged | 0.00 | ||
| AVTE | jade biosciences inc | 0.36 | 1,413,280 | 12,196,600 | reduced | -20.25 | ||
| BBIO | bridgebio pharma inc | 5.98 | 3,845,460 | 199,733,000 | added | 1.18 | ||
| COGT | cogent biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CYTK | cytokinetics inc | 1.47 | 890,445 | 48,938,900 | added | 60.52 | ||
| DSGN | design therapeutics inc | 0.44 | 1,953,550 | 14,710,200 | unchanged | 0.00 | ||
| DYN | dyne therapeutics inc | 1.03 | 2,718,100 | 34,384,000 | added | 80.49 | ||
| ELEV | elevation oncology inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EOLS | evolus inc | 0.48 | 2,630,660 | 16,152,300 | added | 8.01 | ||
| ERAS | erasca inc | 1.49 | 22,729,400 | 49,550,200 | unchanged | 0.00 | ||
| HLVX | hillevax inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||